Addex Therapeutics Ltd

ADXN

CH0029850754

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:31:30 2024-04-26 am EDT			5-day change	1st Jan Change
0.1155 ^CHF	+0.43%		-23.26%	+151.09%

Apr. 24	Top Premarket Decliners	MT
Apr. 18	Transcript : Addex Therapeutics Ltd, 2023 Earnings Call, Apr 18, 2024

Addex Therapeutics : ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy

January 21, 2021 at 01:00 am EST

(MORE TO FOLLOW) Dow Jones Newswires

January 21, 2021 01:00 ET (06:00 GMT)

Latest news about Addex Therapeutics Ltd

Top Premarket Decliners	Apr. 24	MT
Transcript : Addex Therapeutics Ltd, 2023 Earnings Call, Apr 18, 2024	Apr. 18
Addex Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Addex Therapeutics Logs Decline in FY23 Net Loss; Revenue Rises	Apr. 18	MT
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update	Apr. 18	DJ
ADRs End Higher; Biophytis Climbs 30%	Apr. 09	DJ
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	Apr. 09	MT
Top Premarket Gainers	Apr. 09	MT
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%	Apr. 08	DJ
Powell Speech Eyed, Intel Weighs on Sentiment as US Equity Futures Waver Premarket	Apr. 03	MT
Top Premarket Gainers	Apr. 03	MT
Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders	Apr. 03	CI
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders	Apr. 03	DJ
ADRs Close Lower, Lixiang Education Holding Co. Ltd. Declines 19.6%	Mar. 08	DJ
Addex Therapeutics Plans Sale of American Depositary Shares	Jan. 31	MT
ADRs Close Lower; Jianpu Technology Declines 21%	Jan. 30	DJ
Top Premarket Decliners	Jan. 30	MT
ADRs End Higher; Argo Blockchain Climbs 22%	Jan. 26	DJ
ADRs Close Higher; Addex Therapeutics Climbs 21%	Jan. 25	DJ
ADRs End higher; Amarin Climbs 33%	Jan. 10	DJ
Transcript : Addex Therapeutics Ltd, Q3 2023 Earnings Call, Nov 29, 2023	Nov. 29
Addex Therapeutics Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
Addex Therapeutics' ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients	Nov. 14	CI
Addex Therapeutics Restores Compliance with Nasdaq's Minimum Bid Price Requirement	Nov. 08	MT
Addex Therapeutics to Effect ADS Ratio Change on Monday	23-10-20	MT

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Companyâs clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsonâs disease and mGlu3 PAM for neurodegenerative disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.115 CHF

Average target price

0.16 CHF

Spread / Average Target

+39.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ADDEX THERAPEUTICS LTD	+151.09%	16.15M
IQVIA HOLDINGS INC.	+1.93%	42.59B
MODERNA, INC.	+7.50%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+9.12%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.10%	18.17B
MEDPACE HOLDINGS, INC.	+27.19%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.09%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.74%	11.1B

Other Biotechnology & Medical Research

Addex Therapeutics Ltd

Equities

ADXN

CH0029850754

Biotechnology & Medical Research

Addex Therapeutics : ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy

Latest news about Addex Therapeutics Ltd

Chart Addex Therapeutics Ltd

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research